Patents by Inventor Hakon Leffler

Hakon Leffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Galactoside inhibitor of galectins
    Patent number: 11919921
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: March 5, 2024
    Assignee: GALECTO BIOTECH AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20220289783
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 15, 2022
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 11377464
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 5, 2022
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20210221836
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: April 2, 2021
    Publication date: July 22, 2021
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil HENDERSON, Tariq SETHI, Alison MACKINNON, Hakon LEFFLER, Ulf NILSSON
  • Alpha-D-galactoside inhibitors of galectins
    Patent number: 10988502
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: April 27, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Hakon Leffler, Ulf Nilsson
  • Alpha-D-galactoside inhibitors of galectins
    Patent number: 10889610
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: January 12, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200407391
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Hybrid galactoside inhibitor of galectins
    Patent number: 10800804
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Inventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Galactoside inhibitor of galectins
    Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • 1,1 ?-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins
    Patent number: 10730902
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 4, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Anders Pedersen, Hans Schambye, Thomas Brimert, Richard Johnsson
  • NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200115410
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 16, 2020
    Inventors: Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 10526360
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 7, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20190375776
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 12, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20190359643
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 10464964
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: November 5, 2019
    Assignee: Galecto Biotech AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Thomas Brimert, Richard Johnsson, Priya Verma
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190315793
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: October 17, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190225638
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: July 25, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Hakon LEFFLER, Ulf NILSSON
  • Hybrid galactoside inhibitor of galectins
    Patent number: 10253059
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 9, 2019
    Assignee: GALECTO BIOTECH AB
    Inventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20180327440
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 15, 2018
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Anders PEDERSEN, Hans SCHAMBYE, Thomas BRIMERT, Richard JOHNSSON
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20170349619
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 7, 2017
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG